| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36bd79febaaa9fcdbd9db9b22bea9431 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1682
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2019-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c16e700318d6260a6e645e8982b827f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_747f1b0417f9d053dbe54f888d4f9eda
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb16ba5c16dca8c03346f73fb82a49d7 |
| publicationDate |
2021-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11123353-B2 |
| titleOfInvention |
Uses of ergosterol combined with gefitinib, preparation methods of liposome and freeze-dried powder thereof |
| abstract |
The present disclosure relates to a drug combination for treating non-small cell lung cancer, in particular to uses of ergosterol combined with gefitinib, and belongs to the technical field of biomedicine. In the present disclosure, the mechanism of action that ergosterol (ERG) combined with gefitinib (GEF) induces apoptosis of non-small cell lung cancer (NSCLC) cells is firstly studied; then an RGG cyclic peptide/R8 peptide modified ERG combined with GEF active drug-loaded targeted liposome delivery system (RGD/R8-ERG/GEF-LIP) is constructed; and the RGD/R8-ERG/GEF-LIP is prepared into a freeze-dried powder to improve stability, quality evaluation and preliminary evaluation of in vitro anti-lung cancer effects are conducted, and a nude mouse lung cancer xenograft model is established for conducting preliminary pharmacodynamic research and in vivo targeting research. |
| priorityDate |
2019-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |